BC Week In Review | Sep 23, 2013
Clinical News

Oblean cetilistat regulatory update

Norgine and partner Takeda said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA from Takeda for Oblean cetilistat to treat obesity in patients with both Type II diabetes and dyslipidemia. Norgine said...
BC Extra | Sep 21, 2013
Company News

Obesity, pain drugs approved in Japan

Norgine B.V. (Amsterdam, the Netherlands) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Oblean cetilistat to treat obesity in patients with both Type II diabetes and dyslipidemia....
BC Week In Review | Nov 5, 2012
Clinical News

Cetilistat: Phase III data

The double-blind, Japanese Phase III CCT-002 trial in obese patients with Type II diabetes and dyslipidemia showed that thrice-daily 120 mg cetilistat met the primary endpoint of reducing average body weight from baseline to week...
BC Extra | Oct 31, 2012
Company News

Takeda seeks cetilistat Japanese approval

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for cetilistat to treat obesity in patients with complications of Type II diabetes and dyslipidemia. In the double-blind,...
BC Week In Review | Feb 28, 2011
Company News

Alizyme, Pharmagenix deal

Grant Thornton U.K. LLP, which is serving as Alizyme's administrator after the biotech entered administration in 2009, disclosed that Pharmagenix acquired Alizyme's ATL-104 for £67,250 ($109,161) last October. The mucositis candidate is a recombinant plant...
BC Week In Review | Oct 26, 2009
Company News

Alizyme, Norgine deal

Norgine acquired Alizyme's lead compound cetilistat for £4.6 million ($7.5 million) in cash, plus undisclosed milestones and royalties. The lipase inhibitor has completed Phase II testing for obesity. The deal was brokered by Grant Thornton...
BC Week In Review | Oct 26, 2009
Financial News

Alizyme financial update

Alizyme was delisted from the London Stock Exchange. Alizyme plc , Cambridge, U.K.   Business: Gastrointestinal, Endocrine   Date announced: 10/15/09  ...
BC Week In Review | Aug 10, 2009
Company News

Alizyme endocrine news

Alizyme entered administration on July 27. The administrators, from Grant Thornton U.K. LLP, said they have been approached by undisclosed parties interested in acquiring lead compound cetilistat . The lipase inhibitor has completed Phase II testing...
BC Week In Review | Jul 13, 2009
Company News

Alizyme management update

Alizyme plc (LSE:AZM), Cambridge, U.K.   Business: Gastrointestinal, Endocrine   Resigned: Tim McCarthy as CEO and a director; Alan Goodman, a director, will oversee the company's day-to-day affairs  ...
BioCentury | Jul 6, 2009
Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 3 mos ended 3/31 4/2/09 Vermillion Inc. (Pink:VRMLQ) Not disclosed $1.9 0.13 9/30/08 $11 (A) Files for Chapter 11 bankruptcy;...
Items per page:
1 - 10 of 183
BC Week In Review | Sep 23, 2013
Clinical News

Oblean cetilistat regulatory update

Norgine and partner Takeda said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA from Takeda for Oblean cetilistat to treat obesity in patients with both Type II diabetes and dyslipidemia. Norgine said...
BC Extra | Sep 21, 2013
Company News

Obesity, pain drugs approved in Japan

Norgine B.V. (Amsterdam, the Netherlands) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Oblean cetilistat to treat obesity in patients with both Type II diabetes and dyslipidemia....
BC Week In Review | Nov 5, 2012
Clinical News

Cetilistat: Phase III data

The double-blind, Japanese Phase III CCT-002 trial in obese patients with Type II diabetes and dyslipidemia showed that thrice-daily 120 mg cetilistat met the primary endpoint of reducing average body weight from baseline to week...
BC Extra | Oct 31, 2012
Company News

Takeda seeks cetilistat Japanese approval

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for cetilistat to treat obesity in patients with complications of Type II diabetes and dyslipidemia. In the double-blind,...
BC Week In Review | Feb 28, 2011
Company News

Alizyme, Pharmagenix deal

Grant Thornton U.K. LLP, which is serving as Alizyme's administrator after the biotech entered administration in 2009, disclosed that Pharmagenix acquired Alizyme's ATL-104 for £67,250 ($109,161) last October. The mucositis candidate is a recombinant plant...
BC Week In Review | Oct 26, 2009
Company News

Alizyme, Norgine deal

Norgine acquired Alizyme's lead compound cetilistat for £4.6 million ($7.5 million) in cash, plus undisclosed milestones and royalties. The lipase inhibitor has completed Phase II testing for obesity. The deal was brokered by Grant Thornton...
BC Week In Review | Oct 26, 2009
Financial News

Alizyme financial update

Alizyme was delisted from the London Stock Exchange. Alizyme plc , Cambridge, U.K.   Business: Gastrointestinal, Endocrine   Date announced: 10/15/09  ...
BC Week In Review | Aug 10, 2009
Company News

Alizyme endocrine news

Alizyme entered administration on July 27. The administrators, from Grant Thornton U.K. LLP, said they have been approached by undisclosed parties interested in acquiring lead compound cetilistat . The lipase inhibitor has completed Phase II testing...
BC Week In Review | Jul 13, 2009
Company News

Alizyme management update

Alizyme plc (LSE:AZM), Cambridge, U.K.   Business: Gastrointestinal, Endocrine   Resigned: Tim McCarthy as CEO and a director; Alan Goodman, a director, will oversee the company's day-to-day affairs  ...
BioCentury | Jul 6, 2009
Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 3 mos ended 3/31 4/2/09 Vermillion Inc. (Pink:VRMLQ) Not disclosed $1.9 0.13 9/30/08 $11 (A) Files for Chapter 11 bankruptcy;...
Items per page:
1 - 10 of 183